Biotech Acquisition Co - FORM 8-K - EX-99.1 - PRESS RELEASE, DATED JANUARY 25, 2021 - January 29, 2021

Attached files

file filename
EX-99.2 - PRESS RELEASE, DATED JANUARY 28, 2021 - Biotech Acquisition Coea134164ex99-2_biotechacq.htm
EX-10.5 - SPONSOR WARRANTS PURCHASE AGREEMENT, DATED JANUARY 25, 2021 BY AND BETWEEN THE C - Biotech Acquisition Coea134164ex10-5_biotechacq.htm
EX-10.4 - ADMINISTRATIVE SUPPORT AGREEMENT, DATED JANUARY 25, 2021, BY AND BETWEEN THE COM - Biotech Acquisition Coea134164ex10-4_biotechacq.htm
EX-10.3 - REGISTRATION RIGHTS AGREEMENT, DATED JANUARY 25, 2021, BY AND BETWEEN THE COMPAN - Biotech Acquisition Coea134164ex10-3_biotechacq.htm
EX-10.2 - INVESTMENT MANAGEMENT TRUST AGREEMENT, DATED JANUARY 25, 2021, BY AND BETWEEN TH - Biotech Acquisition Coea134164ex10-2_biotechacq.htm
EX-10.1 - LETTER AGREEMENT, DATED JANUARY 25, 2021, BY AND AMONG THE COMPANY, ITS OFFICERS - Biotech Acquisition Coea134164ex10-1_biotechacq.htm
EX-4.1 - WARRANT AGREEMENT, DATED JANUARY 25, 2021, BY AND BETWEEN THE COMPANY AND CONTIN - Biotech Acquisition Coea134164ex4-1_biotechacq.htm
EX-3.1 - AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION - Biotech Acquisition Coea134164ex3-1_biotechacq.htm
EX-1.1 - UNDERWRITING AGREEMENT, DATED JANUARY 25, 2021 BY AND BETWEEN THE COMPANY AND CA - Biotech Acquisition Coea134164ex1-1_biotechacq.htm
8-K - CURRENT REPORT - Biotech Acquisition Coea134164-8k_biotechacq.htm

Exhibit 99.1

 

Biotech Acquisition Company Announces

Pricing of $200 Million Initial Public Offering

 

New York, NY, January 25, 2021 – Biotech Acquisition Company (the “Company”), a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or other similar business combination with one or more businesses, today announced the pricing of its initial public offering of 20,000,000 units at a price of $10.00 per unit. Although the Company may pursue a business target in any industry or geographic location, the Company intends to focus its search for a target business in the healthcare sector.

 

The units will be listed on the Nasdaq Capital Market (“Nasdaq”) and trade under the ticker symbol “BIOTU” beginning January 26, 2021. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share. Only whole warrants are exercisable. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “BIOT” and “BIOTW”, respectively. The offering is expected to close on January 28, 2021, subject to customary closing conditions.

 

Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering. The Company has granted the underwriters a 45-day option to purchase up to an additional 3,000,000 units at the initial public offering price to cover over-allotments, if any.

 

The offering is being made only by means of a prospectus, copies of which may be obtained by contacting Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, New York, NY 10022, or by e-mail at prospectus@cantor.com.

 

A registration statement relating to the securities became effective on January 25, 2021.

 

This communication shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

 

About Biotechnology Acquisition Company

 

 

Biotech Acquisition Company (the “Company”), a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or other similar business combination with one or more businesses. Although the Company may pursue a business target in any industry or geographic location, the Company intends to focus its search for a target business in the healthcare sector. The Company believes that this focus will complement its sponsor’s and management team’s background as affiliates of SPRIM Global Investments, a leading life science investment firm in the healthcare industry. The Company expects that its target sector will have a particular focus on life sciences/ biotechnology, healthcare information technology, medical technology and technology-enabled healthcare service sectors.

 

Cautionary Note Concerning Forward-Looking Statements

 

This communication contains statements that constitute “forward-looking statements,” including with respect to the closing of the Company’s proposed initial public offering and the anticipated use of the net proceeds from the offering. No assurance can be given that the offering will be completed on the terms described, or at all, or that the net proceeds will be used as indicated. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s preliminary prospectus relating to the offering, which is included in its registration statement filed with the U.S. Securities and Exchange Commission (“SEC”). Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements after the date of this release, except as required by law.

 

Contacts

 

Michael Shleifer

Stephanie.Kolp@sprim.net

 

Biotech Acquisition Co Reports